Showing results (91-100 of 107) with videos related to
Sort By:
Pageof 11
European Journal of Heart Failure|November 25, 2025
Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programmeAmbarish Pandey, Michael Moroney, Subodh Verma, et al.Archives of Internal Medicine|January 28, 2009
Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failureGunnar H Gislason, Jeppe N Rasmussen, Steen Z Abildstrom, et al.Circulation|November 12, 2023
Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF TrialMikhail N Kosiborod, Subodh Verma, Barry A Borlaug, et al.European Heart Journal|May 13, 2024
Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trialsSanjiv J Shah, Kavita Sharma, Barry A Borlaug, et al.The Lancet. Diabetes & Endocrinology|January 23, 2025
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trialMelanie J Davies, Peter van der Meer, Subodh Verma, et al.Journal of the American College of Cardiology|September 1, 2024
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW TrialRichard E Pratley, Katherine R Tuttle, Peter Rossing, et al.Nature Medicine|June 24, 2024
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trialJohannes F E Mann, Peter Rossing, George Bakris, et al.Lancet (London, England)|September 2, 2024
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trialsMikhail N Kosiborod, John Deanfield, Richard Pratley, et al.European Heart Journal|August 30, 2024
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trialKenneth W Mahaffey, Katherine R Tuttle, Mustafa Arici, et al.Lancet (London, England)|August 24, 2024
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialJohn Deanfield, Subodh Verma, Benjamin M Scirica, et al.Pageof 11